BLFS Stock — BioLife Solutions, Inc.

BioLife Solutions, Inc. (BLFS)

Updated October 7, 2026.

BLFS is a Stock. Total return is -63.2% over the past 36.9 years.

BioLife Solutions is a bioproduction company that develops and manufactures specialized products and services for the cell and gene therapy industry, including biopreservation media, human platelet lysates, cryo-compatible containers, automated thawing and processing equipment, and temperature-controlled shipping containers. The company does not currently have an established distribution program. BioLife Solutions appeals to growth-oriented investors seeking exposure to the expanding cell and gene therapy sector rather than those seeking current income.

BLFS performance

Price and return data through 2026-10-07.

Total return is -63.2% over the past 36.9 years. Over the past year its total return — price change plus distributions reinvested — is 46.8%. Its deepest 1-year drawdown was 37.0%.

BLFS key facts

Asset type

Stock

Asset class

Equity

Inception date

11/22/1989

Distribution frequency

None

Last close

$38.61 (stale; as of 2026-10-07)

Market cap

$1,888,929,887

Average volume

0.0

Beta

1.824

Payout ratio

0.0%

P/E ratio

39.0

Forward P/E

238.0952

EPS

$0.99

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BLFS risks and drawbacks

The deepest 1-year drawdown on record here is 37.0%.

Who may consider BLFS — and who may not

It is a weaker fit for investors who need monthly cash flow (BLFS does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BLFS

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions